Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

Status Completed

Clinical Trial Summary

The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis. It might also help doctors tell whether or not cancer has spread to these lymph nodes. It might allow radiotherapy to be delivered more accurately.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00188695
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	April 2004
Completion date	March 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04964271` - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed	`NCT02546908` - A Registry of Participants With Prostate Cancer in Asia
Completed	`NCT04838626` - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection	Phase 2/Phase 3
Recruiting	`NCT03101176` - Multiparametric Ultrasound Imaging in Prostate Cancer	N/A
Completed	`NCT01683994` - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Completed	`NCT02364531` - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed	`NCT01929655` - Japanese BAY88-8223 Monotherapy Phase II Study	Phase 2
Active, not recruiting	`NCT05022849` - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants	Phase 1
Completed	`NCT03261999` - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer	Phase 3
Terminated	`NCT04907227` - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension	Phase 3
Active, not recruiting	`NCT03587285` - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT02217566` - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy	Phase 2
Not yet recruiting	`NCT04101305` - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Withdrawn	`NCT02905201` - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	N/A
Terminated	`NCT03066154` - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer	Phase 1
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Terminated	`NCT01420965` - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer	Phase 2
Completed	`NCT01441713` - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer	N/A